News & Views
Trials to Test Potential for Immunotherapy Technology
Oct 07 2019
Sydney-based Immutep Ltd, developers of immunotherapy treatments for cancer and autoimmune diseases, is to receive a milestone payment from GSK of GB £4 million (approx AU $7.39 million) related to the first patient being dosed in GSK’s Phase II clinical trial evaluating GSK2831781 in ulcerative colitis.
GSK2831781 is derived from Immutep’s IMP731 antibody, a depleting anti-LAG antibody technology that was exclusively licensed to GSK. Under the terms of the agreement, the Australian biotech is eligible to receive up to GB £64 million (approx AU $118.17 million) in developmental milestone payments as well as single-digit tiered royalties, if commercialisation stages are reached. GSK is responsible for all costs associated with the clinical development and the commercialisation process.
Immutep CEO Marc Voigt, said: “It is very encouraging to see GSK advancing their product candidate in a phase II clinical trial for ulcerative colitis, further validating LAG-3 as a potential target for therapeutics in autoimmune diseases. These partner milestone payments are an important source of non-dilutive funding to the company and this capital will be deployed to further advance our extensive development programs.”
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia